Equity Profile

RVMD

Revolution Medicines, Inc.

Health CareBiotechnology$31.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to generate sales from its products, which is critical for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment. With a market cap of $30 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs through innovative drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1 2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by nearly 25%. Following the announcement, the stock rose by 2.62% the next day, indicating some investor optimism despite the miss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for the upcoming earnings report are cautious, given the company's history of missing EPS estimates. Investors will be looking for any signs of improvement in revenue or cost management.

Bull Case

If the company can demonstrate a significant reduction in losses or an unexpected revenue increase, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide a clear path to profitability, it could result in further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific strategies will the company implement to reduce losses this quarter?

Investors need clear guidance on how the company plans to improve its financial performance, especially given its history of losses.

Will there be any updates on the pipeline of drugs and their expected market launch dates?

Information on drug development timelines can significantly impact investor sentiment and future revenue projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Revolution Medicines to narrow its losses significantly this quarter, driven by operational efficiencies.

Supporting Evidence

The company has a history of surprising investors with better-than-expected operational metrics.

Options pricing suggests a higher expected move than historical averages, indicating potential for a significant reaction.

Key Risk

If the company reports a narrower loss than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce or challenge the company's narrative of moving towards profitability.

Bull Confirmed If

A reduction in EPS losses to below -$2.00 would signal improved financial health and operational efficiency.

Bear Confirmed If

If EPS remains above -$2.50, it could confirm ongoing financial struggles and lead to negative market sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±4.68%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a move of about 4.68%, suggesting that traders expect significant volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 5 of 11 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 5 of 11 faded and 6 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.4%, with a raw directional average of -0.5% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$18.0M

120,000 sh

1 insider

Net

$18.0M

Net selling

Most Active Insiders· 1 open-market trade

See RemarksGOLDSMITH MARK A
$18.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential average stock move of +2.45%, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

Should the company miss expectations again, history indicates an average decline of -0.14%, which could further erode investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on cost-cutting measures and their impact on EPS.
2Any news regarding drug trials and their timelines.
3Management's outlook on revenue growth for the next quarter.
4Details on partnerships or collaborations that could enhance product development.
5Insights into market demand for their current and future drug offerings.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to generate sales from its products, which is critical for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If the company can demonstrate a significant reduction in losses or an unexpected revenue increase, it could lead to a positive market reaction and renewed investor confidence.

Bear Case

Conversely, if the company continues to miss EPS estimates and fails to provide a clear path to profitability, it could result in further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific strategies will the company implement to reduce losses this quarter?

Investors need clear guidance on how the company plans to improve its financial performance, especially given its history of losses.

Will there be any updates on the pipeline of drugs and their expected market launch dates?

Information on drug development timelines can significantly impact investor sentiment and future revenue projections.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Revolution Medicines to narrow its losses significantly this quarter, driven by operational efficiencies.

Supporting Evidence

The company has a history of surprising investors with better-than-expected operational metrics.

Options pricing suggests a higher expected move than historical averages, indicating potential for a significant reaction.

Key Risk

If the company reports a narrower loss than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it will either reinforce or challenge the company's narrative of moving towards profitability.

Bull Confirmed If

A reduction in EPS losses to below -$2.00 would signal improved financial health and operational efficiency.

Bear Confirmed If

If EPS remains above -$2.50, it could confirm ongoing financial struggles and lead to negative market sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±4.68%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a move of about 4.68%, suggesting that traders expect significant volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 5 of 11 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$18.0M

120,000 sh

1 insider

Net

$18.0M

Net selling

Most Active Insiders· 1 open-market trade

See RemarksGOLDSMITH MARK A
$18.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential average stock move of +2.45%, confirming a positive outlook.

In-Line / Cautious

If results come in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

Should the company miss expectations again, history indicates an average decline of -0.14%, which could further erode investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on cost-cutting measures and their impact on EPS.
2Any news regarding drug trials and their timelines.
3Management's outlook on revenue growth for the next quarter.
4Details on partnerships or collaborations that could enhance product development.
5Insights into market demand for their current and future drug offerings.